IPX203
amneal pharma
[]
the therapy is currently under review by the #fda as a potential treatment for #parkinsonsdisease, with a scheduled pdufa date of june 30, 2023. read more on the data presented at #aanam: 
Associate editorial director, @Neurology_Live 🧠 and @CGT_Live 🧬 Host of the #MindMoments podcast 🎧 and @medicalwrldnews Deep Dive 📺